|Articles|June 3, 2015
Bringing a Biologic from the Bench to the Marketplace
Author(s)Randi Hernandez
Michiel E. Ultee of Ulteemit BioConsulting discusses converting an early drug discovery into a product that is ready for clinical testing.
Advertisement
In this video, Michiel E. Ultee, PhD, principal of Ulteemit BioConsulting, discusses converting an early drug discovery into a product that is ready for clinical testing, biologics license applications, and FDA guidance documents.
The video was shot at INTERPHEX 2015 in New York, NY.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Mitigation and Maintenance Protect Against Future Risk
2
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
3
FAQ: Milestones You May Have Missed in the 2025 Biopharma Pipeline
4
Roche Drives Industry Shift With Three-Year Lymphoma Survival Data
5
